Secondary Prevention: Difference between revisions
Jump to navigation
Jump to search
TayyabaAli (talk | contribs) No edit summary |
TayyabaAli (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
Main article: [[Bartter syndrome]] | Main article: [[Bartter syndrome]] | ||
{{CMG}}{{AE}}{{TAM}} | {{CMG}}{{AE}}{{TAM}} | ||
==Overview== | ==Overview== | ||
Latest revision as of 12:18, 7 August 2020
Main article: Bartter syndrome
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
Main Careful monitoring is required since NSAIDs can have significant adverse effects including renal and gastrointestinal toxicity.
Secondary Prevention
Main Careful monitoring is required since NSAIDs can have significant adverse effects including renal and gastrointestinal toxicity.[1]
References
- ↑ Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E; et al. (2015). "Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome". J Am Soc Nephrol. 26 (2): 468–75. doi:10.1681/ASN.2014030293. PMC 4310664. PMID 25012174.